KHKunyan Hao

Kunyan Hao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kunyan Hao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Chengwei Chen

    Liver Disease Center of No. 905 Hospital, Shanghai, 200235, China

    1 shared publication
  • Hong Zhao

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, 8 East Jingshun Road, Chaoyang District, Beijing, China

    1 shared publication
  • Jidong Jia

    Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

    1 shared publication
  • Mengmeng Zhang

    Liver Research Center, Beijing Friendship Hospital, Capital Medical University; Key Laboratory on Translational Medicine on Cirrhosis; National Clinical Research Center for Digestive Diseases, Beijing, China

    1 shared publication
  • Mengqi Li

    Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, 8 East Jingshun Road, Chaoyang District, Beijing, China

    1 shared publication
  • Min Li

    Clinical Epidemiology and EBM Unit, Beijing Friendship Hospital Capital Medical University; Beijing Clinical Research Institute Beijing China

    1 shared publication

Latest Publications

  • Open Access

    Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients

    by Xinyan Zhao, Yan Wang, Rongtao Lai, Xiaojin Wang, Yuecheng Yu, Min Li, Hong Zhao, Zikun Ma, Mengqi Li, Tiantian Guo, et al.

    Background & Aims: The Revised Electronic Causality Assessment Method (RECAM), a computerized update of the Roussel Uclaf Causality Assessment Methodology (RUCAM), was recently proposed. In this study, we validated and compared the utility of the RECAM and RUCAM in Chinese patients with a single conventional or herbal agent-induced liver injury. Methods: In this retrospective multicenter cohort of well-established DILI and non-DILI patients from 5 centers in China, the diagnostic performance of the RUCAM and RECAM was compared by AUC analysis. The consistency was evaluated by weighted kappa. The major causes of discrepancy were explored. Results: A total of 481 DILI and 100 non-DILI patients were included. In total, 62.6% of the DILI cases were induced by conventional agents, and 37.4% were induced by herbs. The RECAM had relatively higher AUC than RUCAM for overall [0.947 (0.926–0.964) vs. 0.867 (0.836–0.893), p=0.0016], conventional agents [0.923 (0.890–0.949) vs. 0.819 (0.775–0.858), p=0.0185], and herbs [0.972 (0.941–0.989) vs.0.911 (0.866–0.944), p=0.0199]. Latency, scores associated with hepatitis B, and hepatotoxicity information of the insulting drugs were the 3 main causes for the inconsistency between RECAM and RUCAM scores. Conclusions: The RECAM had relatively better diagnostic performance than RUCAM, with a higher AUC for Chinese DILI patients. Timely updates of the LiverTox category and refinement of serum markers to exclude hepatitis B activity would further improve the applicability of RECAM in areas where the use of herbs and resolution of past HBV infections are common.